I-MAB (NAS:IMAB)
$ 1.055 -0.04 (-3.64%) Market Cap: 81.84 Mil Enterprise Value: -118.19 Mil PE Ratio: 0 PB Ratio: 0.35 GF Score: 35/100

I-Mab Corporate Call Transcript

Dec 21, 2021 / 01:00PM GMT
Release Date Price: $48.1 (+2.21%)
Tianyi Zhang
I-Mab - Executive Director of IR

Good morning or good evening. Thank you for standing by. This is Tianyi Zhang, IR Head of I-Mab Pharma. Thank you for joining the conference call today. Yesterday, I-Mab announced strengthening of the management team to accelerate global pipeline development and the transformation towards commercialization.

Dr. Andrew Zhu, a internationally renowned oncologist was appointed as President and Board of Director to lead the company's R&D organization, focusing on global pipeline developments. Today's call, we will have the management team to give you more insights of the new appointment and the company's development strategy.

Joining me today from I-Mab's senior management team include Dr. Jingwu Zhang, Founder and Chairman of I-Mab; Dr. Andrew Zhu, President of I-Mab; and Mr. John Long, CFO of I-Mab. Now I'd like to turn the call to Dr. Jingwu Zhang, Founder and Chairman of I-Mab. Dr. Zhang, please?

Jingwu Zhang Zang
I-Mab - Founder & Chairman

Thank you, Tianyi. Good evening or good

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot